Abstract Low-density lipoprotein cholesterol (LDL-C) is a proven causative factor for developing atherosclerotic cardiovascular disease. Individuals with genetic conditions associated lifelong very low LDL-C levels can be healthy. We now possess the pharmacological armamentarium (statins, ezetimibe, PCSK9 inhibitors) to reduce an unprecedented extent. Increasing numbers of patients are expected...

Purpose: The aim of this study is to analyze the utility lipid parameters individually and low-density lipoprotein cholesterol/high-density cholesterol (LDL-C/HDL-C) ratio as a possible risk marker for intracerebral hemorrhages (ICH).
 Materials Methods: This was multicenter, retrospective case-control that included 226 patients with ICH controls. Lipid were evaluated after 12 h fasting in...

BACKGROUND Small dense low-density lipoprotein (sd-LDL) is an atherogenic lipoprotein closely associated with an increased risk of cardiovascular diseases. However, a precise analysis of the actual amount of sd-LDL-cholesterol (sd-LDL-C) in patients with metabolic syndrome (MS) has not been performed. METHODS AND RESULTS Among 214 patients enrolled in the present study, 101 patients (47%) met...

AIMS Our study addressed potential associations between fatty liver and small, dense low-density lipoprotein cholesterol (sd-LDL-C) levels using a cross-sectional analysis. METHODS We enrolled 476 male subjects. Serum sd-LDL-C concentrations were determined using precipitation assays. RESULTS Subjects were divided into four groups based on triglyceride (TG) and LDL-C levels: A, TG < 150 mg/...

Despite the importance of accurate assessment for low-density lipoprotein cholesterol (LDL-C), the Friedewald formula has primarily been used as a cost-effective method to estimate LDL-C when triglycerides are less than 400 mg/dL. In a recent study, an alternative to the formula was proposed to improve estimation of LDL-C. We evaluated the performance of the novel method versus the Friedewald f...

Low-density lipoprotein (LDL) indubitably contributes causally to atherosclerosis, a leading challenge health worldwide. Interventions that lower LDL cholesterol (LDL-C) have made remarkable inroads against this global scourge. Recent therapeutic advances achieved ever levels of LDL-C. Improved cardiovascular outcomes continue accrue from these interventions. In particular, the discovery role p...

1022 L ow-density lipoproteins (LDLs) are a proven causal risk factor for the development of atherosclerotic cardiovascu-lar disease. Plasma levels of LDL cholesterol (LDL-C) and its major protein, apolipoprotein B (apoB), are positively associated with incident cardiovascular events. 1 Individuals with genetic conditions of extremely high LDL-C develop premature cardiovascular disease; convers...

Background and Aims : Angiopoietin-like protein 3 (ANGPTL3) inhibition reduces LDL-cholesterol (LDL-C), triglycerides (TG) HDL-C in patients with hyperlipidemia. Post-prandially, ANGPTL8 forms a complex ANGPTL3; the ANGPTL3/8 inhibits lipoprotein lipase 100-fold more potently circulates at much lower levels than ANGPTL3 alone. This phase 1 study assessed safety pharmacology of single ascending ...

BACKGROUND Friedewald equation is the most widely used method for estimating low-density lipoprotein cholesterol (LDL-C) level. However, due to potential over- or underestimation, many studies have used a modified equation. This study aimed to compare estimates by 4 different equations to directly measured LDL-C concentrations in order to propose the most appropriate method for LDL-C estimation...